Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)	9 Months Ended
	May 31, 2016	May 31, 2015
Cash flows from operating activities
Net income	$ 4,161,161	$ 3,351,558
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization of property and equipment	148,442	168,585
Amortization of capitalized computer software development costs	735,579	748,730
Amortization of Intellectual property	566,250	566,250
Stock-based compensation	234,616	230,501
Deferred income taxes	(4,910)	377,666
(Increase) decrease in
Accounts receivable	(2,988,866)	(1,347,791)
Revenues in excess of billings	(244,772)	(368,170)
Prepaid income taxes	(108,690)	748,359
Prepaid expenses and other assets	93,554	7,106
Increase (decrease) in
Accounts payable	(24,411)	(56,838)
Accrued payroll and other expenses	81,212	(357,397)
Accrued bonus	(30,250)	(48,000)
Billings in excess of revenues	5,911	(253,318)
Accrued income taxes	(43,602)	178,894
Other liabilities	(14,894)	(14,895)
Deferred revenue	182,321	11,796
Net cash provided by (used in) operating activities	2,748,651	3,943,036
Cash flows from investing activities
Purchases of property and equipment	(32,317)	(35,620)
Cash used to purchase Cognigen	0	(2,080,000)
Cash received in acquisition	0	190,184
Capitalized computer software development costs	(815,582)	(976,350)
Net cash provided by (used in) investing activities	(847,899)	(2,901,786)
Cash flows from financing activities
Payment of dividends	(2,552,175)	(2,528,416)
Payments on contracts payable	(750,000)	(750,000)
Proceeds from the exercise of stock options	129,831	50,833
Net cash (used in) financing activities of continuing operations	(3,172,344)	(3,227,583)
Net increase (decrease) in cash and cash equivalents	(1,271,592)	(2,186,333)
Cash and cash equivalents, beginning of year	8,551,275	8,614,929
Cash and cash equivalents, end of period	7,279,683	6,428,596
Supplemental disclosures of cash flow information
Interest paid	0	0
Income taxes paid	2,186,159	320,707
Non-Cash Investing and Financing
Stock issued for acquisition of Cognigen Corporation	0	3,277,170
Creation of contract liability for acquisition of Cognigen Corporation	$ 0	$ 1,854,404